Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5375 Medpace Way CINCINNATI OH 45227-1543 |
Tel: | N/A |
Website: | https://investor.medpace.com |
IR: | See website |
Key People | ||
August J. Troendle Chairman of the Board, Chief Executive Officer | Jesse J. Geiger President | Kevin M. Brady Chief Financial Officer, Treasurer |
Susan E. Burwig Executive Vice President - Operations | Stephen P. Ewald General Counsel, Corporate Secretary |
Business Overview |
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia. |
Financial Overview |
For the nine months ended 30 September 2024, Medpace Holdings Inc revenues increased 13% to $1.57B. Net income applicable to common stockholders increased 41% to $287.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest Expense/Income - Net increase from $2.3M (expense) to $17.1M (income), Miscellaneous (expense) income. |
Employees: | 5,900 as of Sep 30, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10,349M as of Sep 30, 2024 |
Annual revenue (TTM): | $2,071M as of Sep 30, 2024 |
EBITDA (TTM): | $437.53M as of Sep 30, 2024 |
Net annual income (TTM): | $365.57M as of Sep 30, 2024 |
Free cash flow (TTM): | $535.65M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 31,011,528 as of Sep 30, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |